Early Circulating Tumor DNA Dynamics Predict Fruquintinib Efficacy in Refractory Metastatic Colorectal Cancer Before Imaging - Takeaways - MDSpire

Early Circulating Tumor DNA Dynamics Predict Fruquintinib Efficacy in Refractory Metastatic Colorectal Cancer Before Imaging

  • By

  • Hou, Hebin

  • Liu, Pingping

  • Dong, Xiaohuan

  • Gai, Wei

  • Jiang, Peng

  • Yang, Fan

  • Hao, Chongli

  • May 20, 2026

  • 0 min

Share

  • 1

    This study evaluated circulating tumor DNA dynamics as predictors of fruquintinib efficacy in refractory metastatic colorectal cancer.

  • 2

    Among 120 enrolled patients, 107 completed day-28 circulating tumor DNA testing, revealing significant changes in variant allele frequency.

  • 3

    Patients with clearance or decrease in circulating tumor DNA had higher disease control rates and lower progression risk compared to stable/increase.

  • 4

    Circulating tumor DNA stratification improved model discrimination for progression-free and overall survival.

  • 5

    Common adverse events during fruquintinib treatment included hypertension, hand-foot skin reaction, and fatigue, indicating acceptable tolerability.

Original Source(s)

Early Circulating Tumor DNA Dynamics Predict Fruquintinib Efficacy in Refractory Metastatic Colorectal Cancer Before Imaging

  • by Hou, Hebin , Liu, Pingping , Dong, Xiaohuan , Gai, Wei , Jiang, Peng , Yang, Fan , Hao, Chongli

  • May 20, 2026

Related Content

Case Report: ETV6 c.744del gene mutation acute lymphoblastic leukemia in identical twins

Intracranial angiomatoid fibrous histiocytoma in a 2-month-old infant: a rare case report

Access to Specialty Cancer Care and Plan Disenrollment Among Medicare Beneficiaries